207 related articles for article (PubMed ID: 19759127)
1. Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.
Wang FZ; Roy D; Gershburg E; Whitehurst CB; Dittmer DP; Pagano JS
J Virol; 2009 Dec; 83(23):12108-17. PubMed ID: 19759127
[TBL] [Abstract][Full Text] [Related]
2. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.
Whitehurst CB; Sanders MK; Law M; Wang FZ; Xiong J; Dittmer DP; Pagano JS
J Virol; 2013 May; 87(9):5311-5. PubMed ID: 23449792
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
Zacny VL; Gershburg E; Davis MG; Biron KK; Pagano JS
J Virol; 1999 Sep; 73(9):7271-7. PubMed ID: 10438815
[TBL] [Abstract][Full Text] [Related]
4. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.
Gershburg E; Hong K; Pagano JS
Antimicrob Agents Chemother; 2004 May; 48(5):1900-3. PubMed ID: 15105156
[TBL] [Abstract][Full Text] [Related]
5. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.
Gershburg E; Pagano JS
J Virol; 2002 Feb; 76(3):998-1003. PubMed ID: 11773375
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
Reitsma JM; Terhune SS
Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.
Williams SL; Hartline CB; Kushner NL; Harden EA; Bidanset DJ; Drach JC; Townsend LB; Underwood MR; Biron KK; Kern ER
Antimicrob Agents Chemother; 2003 Jul; 47(7):2186-92. PubMed ID: 12821466
[TBL] [Abstract][Full Text] [Related]
10. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.
Lin JC; Smith MC; Pagano JS
J Virol; 1984 Apr; 50(1):50-5. PubMed ID: 6321799
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus infections: prospects for treatment.
Gershburg E; Pagano JS
J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
[TBL] [Abstract][Full Text] [Related]
12. Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression.
Ballout M; Germi R; Fafi-Kremer S; Guimet J; Barguès G; Seigneurin JM; Morand P
J Virol Methods; 2007 Jul; 143(1):38-44. PubMed ID: 17368820
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses.
Pagano JS; Datta AK
Am J Med; 1982 Jul; 73(1A):18-26. PubMed ID: 6285710
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus: inhibition of replication by three new drugs.
Lin JC; Smith MC; Cheng YC; Pagano JS
Science; 1983 Aug; 221(4610):578-9. PubMed ID: 6306771
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
Bigley TM; Reitsma JM; Terhune SS
J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
[TBL] [Abstract][Full Text] [Related]
16. Activity of penciclovir against Epstein-Barr virus.
Bacon TH; Boyd MR
Antimicrob Agents Chemother; 1995 Jul; 39(7):1599-602. PubMed ID: 7492112
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.
Lin JC; Machida H
Antimicrob Agents Chemother; 1988 Jul; 32(7):1068-72. PubMed ID: 2847639
[TBL] [Abstract][Full Text] [Related]
18. Screening of drugs inhibiting Epstein-Barr virus replication.
Liu MY; Yen HK; Chern JW; Tsai CH; Yang CS; Chen JY
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1996 May; 29(2):80-9. PubMed ID: 10592789
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.
Verma D; Thompson J; Swaminathan S
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3609-14. PubMed ID: 26976570
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus.
Lin JC; Nelson DJ; Lambe CU; Choi EI
J Virol; 1986 Nov; 60(2):569-73. PubMed ID: 3021990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
